MCID: DRG024
MIFTS: 42

Drug Allergy

Categories: Immune diseases

Aliases & Classifications for Drug Allergy

MalaCards integrated aliases for Drug Allergy:

Name: Drug Allergy 12 15 17
Drug Allergies 62
Allergy Drug 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0060500

Summaries for Drug Allergy

Disease Ontology : 12 A hypersensitivity reaction type I disease triggered by a drug.

MalaCards based summary : Drug Allergy, also known as drug allergies, is related to beta-lactam allergy and rocuronium allergy. An important gene associated with Drug Allergy is IL5 (Interleukin 5), and among its related pathways/superpathways are Th2 Differentiation and IL4-mediated signaling events. The drugs Morphine and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are digestive/alimentary and hematopoietic system

Wikipedia : 74 A drug allergy is an allergy to a drug, most commonly a medication, and is a form of adverse drug... more...

Related Diseases for Drug Allergy

Diseases related to Drug Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 635)
# Related Disease Score Top Affiliating Genes
1 beta-lactam allergy 32.7 IL4R IGHE ATP12A
2 rocuronium allergy 32.1 PEDS1 CD63
3 chlorhexidine allergy 32.0 PEDS1 ENPP3
4 cephalosporin allergy 31.9 PEDS1 MRGPRX2 ENPP3
5 oxirane allergy 31.5 PEDS1 ENPP3 CD63 ALB
6 diclofenac allergy 31.5 ENPP3 CD63 ATP4A ATP12A ALB
7 ige responsiveness, atopic 30.9 IL5 IL4R IGHE
8 angioedema 30.8 IL5 IGHE ACE
9 penicillin allergy 30.8 IL4R IGHE ATP4A ATP12A
10 amoxicillin allergy 30.4 IGHE ENPP3 CD63
11 allergic hypersensitivity disease 30.4 TPT1 PEDS1 IL5 IL4R IGHE CYP3A4
12 urticaria 30.3 TPT1 IL5 IGHE ENPP3 CRP CD40LG
13 atopic keratoconjunctivitis 30.2 IL5 IGHE
14 food allergy 30.1 TPT1 IL5 IL4R IGHE ENPP3 ALB
15 peanut allergy 30.0 PEDS1 IL5 IGHE
16 bullous skin disease 30.0 IL5 CD40LG CD4
17 allergic rhinitis 30.0 TPT1 IL5 IL4R IGHE
18 chlamydia 29.9 IL5 CRP CD40LG
19 rhinitis 29.9 TPT1 IL5 IL4R IGHE CYP3A4 ALB
20 peptic ulcer disease 29.9 INS ATP4A ATP12A ALB
21 viral exanthem 29.8 CRP CD40LG CD4
22 purpura 29.6 CRP CD40LG ACE
23 chorioretinitis 29.6 CD40LG CD4 ACE
24 acquired immunodeficiency syndrome 29.6 IL4R CRP CD40LG CD4 ALB
25 autoimmune disease 29.6 TPMT INS IL5 CRP CD40LG
26 bronchitis 29.5 IL5 IGHE CRP CD40LG ALB
27 anxiety 29.5 INS CYP3A4 CRP ACE
28 interstitial lung disease 29.5 IL5 CRP CD40LG ALB
29 active peptic ulcer disease 29.5 CYP3A4 CRP ATP4A ATP12A ALB
30 congestive heart failure 29.5 INS CRP ALB ACE
31 skin disease 29.3 IL5 CRP CD40LG CD4 ALB
32 iridocyclitis 29.3 CRP CD40LG CD4 ACE
33 diarrhea 29.3 IL5 GPT CYP3A4 CD40LG ALB
34 severe acute respiratory syndrome 29.3 GPT CRP CD40LG ACE
35 egg allergy 29.2 PEDS1 IL5 IGHE ENPP3 CD4
36 dermatitis, atopic 29.2 TPMT PEDS1 IL5 IL4R IGHE CD4
37 inherited metabolic disorder 29.2 INS GPT CRP ALB ACE
38 pollen allergy 29.2 PEDS1 IL5 IL4R IGHE ENPP3 CD63
39 collagen disease 29.2 HSPG2 CRP CD40LG
40 pneumonia 29.0 IL5 GPT CRP CD40LG ALB ACE
41 otitis media 28.9 IL5 IGHE GPT CRP CD40LG ALB
42 constipation 28.9 INS GPT CYP3A4 CRP ATP4A ATP12A
43 lung disease 28.9 INS IL5 CRP CD40LG ALB ACE
44 asthma 28.8 TPT1 INS IL5 IL4R IGHE CYP3A4
45 inflammatory bowel disease 28.8 TPMT IL5 IL4R CRP CD40LG ALB
46 exanthem 28.7 GPT CYP3A4 CRP CD40LG CD4 ATP4A
47 pancytopenia 28.7 TPMT CRP CD40LG CD4 ALB ACE
48 syphilis 28.5 GPT CRP CD40LG CD4 ALB ACE
49 dysentery 28.4 GPT CRP CD40LG CD4 ATP4A ATP12A
50 heart disease 28.2 INS GPT CRP CD40LG CD4 ALB

Graphical network of the top 20 diseases related to Drug Allergy:



Diseases related to Drug Allergy

Symptoms & Phenotypes for Drug Allergy

MGI Mouse Phenotypes related to Drug Allergy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.96 ALB ATP12A ATP4A CD4 CD63 ENPP3
2 hematopoietic system MP:0005397 9.9 ACE ATP4A CD4 CD40LG ENPP3 HSPG2
3 homeostasis/metabolism MP:0005376 9.8 ACE ALB ATP12A ATP4A CD4 CD40LG
4 immune system MP:0005387 9.4 ACE ALB ATP4A CD4 CD40LG CRP

Drugs & Therapeutics for Drug Allergy

Drugs for Drug Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4 57-27-2 5288826
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Linagliptin Approved Phase 4 668270-12-0 10096344
7
Empagliflozin Approved Phase 4 864070-44-0
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Canagliflozin Approved Phase 4 842133-18-0
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Metronidazole Approved Phase 4 443-48-1 4173
13 Anti-Inflammatory Agents Phase 4
14 Analgesics Phase 4
15 Gastrointestinal Agents Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Antiemetics Phase 4
18 glucocorticoids Phase 4
19 Narcotics Phase 4
20 Analgesics, Opioid Phase 4
21 Laxatives Phase 4
22 Cathartics Phase 4
23 Viscosupplements Phase 4
24 Adjuvants, Immunologic Phase 4
25 Carboxymethylcellulose Sodium Phase 4
26 Protective Agents Phase 4
27 Immunologic Factors Phase 4
28 Hormones Phase 4
29 Hormone Antagonists Phase 4
30 HIV Protease Inhibitors Phase 4
31
protease inhibitors Phase 4
32 Dipeptidyl-Peptidase IV Inhibitors Phase 4
33 Anti-Obesity Agents Phase 4
34 Sodium-Glucose Transporter 2 Inhibitors Phase 4
35 Incretins Phase 4
36 Lipid Regulating Agents Phase 4
37 Sitagliptin Phosphate Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Anti-Infective Agents Phase 4
41 Cephalosporins Phase 4
42 Antitubercular Agents Phase 4
43
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
44
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
45
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
46 Ethiodized oil Approved, Investigational Phase 2, Phase 3 8008-53-5
47
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
48
Abacavir Approved, Investigational Phase 3 136470-78-5 441300 65140
49
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
50
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
2 Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine in Patients Undergoing Major Abdominal Cancer Surgery Completed NCT02566096 Phase 4 transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
3 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Completed NCT01966640 Phase 4
4 Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study Completed NCT02773251 Phase 4 hyaluronic acid-carboxymethylcellulose
5 Comparision of Addition of Dexamethasone vs Bicarbonate to Intracuff Lignocaine 2% in Terms of Extubation Characteristics and Patient Satisfaction Undergoing General Anaesthesia Completed NCT03833947 Phase 4 lignocaine+bicarbonate;lignocaine+dexamethasone
6 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment Active, not recruiting NCT02041234 Phase 4 Incretin analogues;Xenical;SGLT2 inhibitors;DPP-4 Inhibitors
7 Partial Oral Antibiotic Treatment for Bacterial Brain Abscess: An Open-label Randomised Non-inferiority Trial Not yet recruiting NCT04140903 Phase 4 Early transition to oral antibiotics;Standard treatment of intravenous antibiotics
8 The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Affects on Cerebral Blood Flow Withdrawn NCT01400256 Phase 4 Valsartan
9 Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma Unknown status NCT00522405 Phase 2, Phase 3
10 Improving Safety by Basic Computerizing Outpatient Prescribing Completed NCT01091038 Phase 2, Phase 3
11 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
12 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
13 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers Completed NCT00569777 Phase 3
14 A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV-1 Infected Subjects. Completed NCT00053638 Phase 3 efavirenz;tenofovir;abacavir/lamivudine
15 Effectiveness of 3 Day Amoxycillin Versus 5 Day co-Trimoxazole in the Treatment of Non-Severe Pneumonia in Children Aged 2- 59 Months of Age: - A Multi-Centric Open Labeled Trial Completed NCT00396526 Phase 3 Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
16 Efficacy and Safety of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain in Patients Undergoing Modified Radical Mastectomy Completed NCT02620371 Phase 3
17 Randomized Double Blind Placebo Controlled Trial of Amoxycillin in the Treatment of Non-Severe Pneumonia With Wheeze in Children Aged 2- 59 Months of Age: A Multi-Centric Study Completed NCT00407394 Phase 3 Amoxycillin
18 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
19 Evaluation of the Effects of Two Types of Fluid in the Recovery From Anaesthesia. Completed NCT01122459 Phase 3
20 Aspirin on CTCs of Advanced Breast and Colorectal Cancer Unknown status NCT02602938 Phase 2 Aspirin
21 Two and Three Dimensional Contrast-Enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation Completed NCT02440334 Phase 2 Optison
22 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
23 Efficacy of Dexmedetomidine as an Adjuvant to Local Anesthetic Agent in Scalp Block and Scalp Infiltration to Control Post Craniotomy Pain Completed NCT02866409 Phase 2 Dexmedetomidine;Bupivacaine
24 Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection (Part A) Not yet recruiting NCT04267809 Phase 2 Metformin Hydrochloride
25 Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis Terminated NCT00918931 Phase 2 Obatoclax Mesylate
26 Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization Completed NCT02118987 Phase 1 Omalizumab
27 Role of Airway Tissue Temperature in Asthma Exacerbation Recruiting NCT02401074 Phase 1
28 Drug Challenges Without Prior Skin Testing Active, not recruiting NCT03158831 Phase 1 Placebo-Controlled Graded Drug Challenge
29 The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia Unknown status NCT03157180
30 Improved Management Based on Pathophysiology of Drug Hypersensitivity in Childhood Unknown status NCT02031120
31 To Effect and Safety of Continuous Venovenous Hemofiltration (CVVH) Versus Conventional Treatment for Acute Severe Hypernatremia in Critical Ill Patients: A Randomized Clinical Trial Unknown status NCT02449382 Control group
32 Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section: a Randomized Comparison of Metoclopramide or Ondansetron Alone or in the Combination With Dexamethasone. Unknown status NCT00892996 dexamethasone;dexamethasone 5 mg
33 Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State. Unknown status NCT00339703
34 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
35 Effect of Periprosthetic Fracture on Hip Function After Femoral Neck-preserving Total Hip Arthroplasty: a Prospective, Single-center, Self-controlled Trial With 2-year Follow-up Unknown status NCT02981823
36 Supercapsular Percutaneously Assisted Total Hip Approach for the Elderly With Femoral Neck Fractures: a Prospective, Open-label, Randomized, Controlled Clinical Trial Unknown status NCT03134664
37 Digital Navigation Enhances Cervical Pedicle Screw Placement Accuracy and Safety: A Randomized Controlled Trial Unknown status NCT02880839
38 Porous Tantalum Rods Improve the Hip Joint Function of Patients With Avascular Necrosis of the Femoral Head After Femoral Neck Fracture Surgery: a Randomized Controlled Trial Unknown status NCT02877472
39 Cobalt Alloy Pedicle Screw Implantation for Severe Kyphosis Deformity in Spinal Tuberculosis: a Selfcontrolled Trial Unknown status NCT02971644
40 Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events Unknown status NCT02733965
41 Clinical Trial in Assigning of Tacrolimus Dosage Regimen According to CYP3A5 Genotype in Kidney Transplant Recipients Unknown status NCT03173820
42 The Optimized Diagnostic Methods for the Confirmation of Beta-lactam Hypersensitivity in Thailand Completed NCT01667055
43 Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment Completed NCT01520181 Beta-lactam oral challenge
44 Quality of Life of Patients With a History of Drug Allergy in Thailand Completed NCT01666470
45 Multiple Drug Hypersensitivity Syndrome in a Large Database Completed NCT03784482
46 Drug Hypersensitivity Reactions To Cephalosporins Completed NCT04421638
47 Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs Completed NCT02556320 anti-epileptic drug
48 Construction and Validation of a Simplified Provocation Tests for the Diagnosis of Non Steroidal Anti-inflammatory Drugs (NSAID) Hypersensitivity Completed NCT03743220
49 An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis. Completed NCT00517946 pseudoephedrine hydrochloride;cetirizine hydrochloride
50 Construction and Validation of a Simplified Provocation Test for the Diagnosis of Paracetamol Hypersensitivity Completed NCT03771118

Search NIH Clinical Center for Drug Allergy

Genetic Tests for Drug Allergy

Anatomical Context for Drug Allergy

MalaCards organs/tissues related to Drug Allergy:

40
Testes, Skin, T Cells, Liver, Breast, Bone, Brain

Publications for Drug Allergy

Articles related to Drug Allergy:

(show top 50) (show all 2119)
# Title Authors PMID Year
1
Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. 61 54
19254289 2009
2
Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. 54 61
18991696 2008
3
Detection of serum histamine-releasing factors in a patient with idiopathic anaphylaxis and multiple drug allergy syndrome. 54 61
17460952 2007
4
[Pharmacogenetics: Important aspects for dermatology]. 54 61
15645192 2005
5
Sera from patients with multiple drug allergy syndrome contain circulating histamine-releasing factors. 54 61
12876410 2003
6
The role of immunoglobulin E in allergy and asthma. 54 61
11704610 2001
7
In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. 54 61
11251565 2001
8
Distinct serum cytokine levels in drug- and measles-induced exanthema. 54 61
10592468 1999
9
Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. 54 61
8309946 1993
10
[The determination of specific IgE in allergy diagnosis. The clinical significance of specific IgE in drug allergies]. 61 54
2151433 1990
11
Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. 61
32524611 2020
12
Drug allergy delabeling in the clinical setting: An all-hands-on-deck opportunity. 61
32147524 2020
13
Alpha-gal syndrome: an emerging cause of food and drug allergy. 61
32542789 2020
14
Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes. 61
32526307 2020
15
Drug Allergy in Children: What Should We Know? 61
32024327 2020
16
Are you sure that it is a drug allergy? 61
32475106 2020
17
Does delayed urticaria induced by drug allergy exist? 61
32505526 2020
18
Drug allergy labeling and delabeling in the coronavirus disease 2019 era: What is important and what do we need to know. 61
32448437 2020
19
Development of Machine Learning Algorithms to Predict Patient Dissatisfaction After Primary Total Knee Arthroplasty. 61
32564970 2020
20
A generalized purpuric eruption with histopathologic features of leucocytoclastic vasculitis in a patient severely ill with COVID-19. 61
32531119 2020
21
Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative. 61
32548204 2020
22
Improving Allergy Documentation: A Retrospective Electronic Health Record System-Wide Patient Safety Initiative. 61
32487880 2020
23
[Analysis of Related Factors of Adverse Transfusion Reactions]. 61
32552967 2020
24
β-Lactam allergy testing and delabeling-Experiences and lessons from Singapore. 61
32506796 2020
25
Post-marketing safety-related regulatory actions on first-in-class drugs: A double-cohort study. 61
31846100 2020
26
Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. 61
31749148 2020
27
The economics of drug allergy. 61
32452890 2020
28
Symmetrical drug-related intertriginous and flexural exanthema: A little-known drug allergy. 61
32376489 2020
29
Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. 61
31865444 2020
30
Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. 61
32407593 2020
31
Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors. 61
31722513 2020
32
Hypersensitivity Reactions to Monoclonal Antibodies in Children. 61
32408641 2020
33
Allergy to beta-lactam antibiotics in children: Risk factors for a positive diagnostic work-up. 61
32460994 2020
34
Omalizumab and other biologics in drug desensitization. 61
32398420 2020
35
The use of in vivo and in vitro tests in children with beta lactam allergy. 61
32473813 2020
36
Adherence to Antibiotic Prophylaxis for Percutaneous Transhepatic Cholangiography: A Single-Centre Experience. 61
32523844 2020
37
Prevalence, Incidence, and Sensitization Profile of β-lactam Antibiotic Allergy in Hong Kong. 61
32374398 2020
38
Adding a second skin prick test reading and modifying the Cut-off for Beta-lactam-specific IgE enhances the sensitivity in the routine diagnostic work-up for immediate Beta-lactam-hypersensitivity. 61
32462721 2020
39
The CD45dim/CD123bright/HLADRneg BAT in the Anti-histamine Drug Allergy. 61
32372634 2020
40
Naphthalimide Dyes with Orthogonal Functional Groups for "Click" Chemistry: Attachment to Solid Supports and Applications in Drug Allergy Diagnosis. 61
32253834 2020
41
Community pharmacy sales of non-prescribed antibiotics in Riyadh, Saudi Arabia: a simulated patient study. 61
32301067 2020
42
Gap between patient expectation and perception during pharmacist-patient communication at community pharmacy. 61
32266556 2020
43
High-cost, high-need patients: the impact of reported penicillin allergy. 61
32270982 2020
44
Perioperative anaphylaxis and investigations: a local study in Hong Kong. 61
31788702 2020
45
Categorization of adverse drug reactions in electronic health records. 61
32302059 2020
46
A novel whole blood based method for lymphocyte transformation test in drug allergies. 61
31958448 2020
47
Skin tests and challenge-based drug allergy diagnosis: a retrospective study of patients with confirmed drug allergy. 61
31594290 2020
48
Proactive management of penicillin and other antibiotic allergies. 61
32122444 2020
49
Selective immunoglobulin A deficiency (SIgAD) primarily leads to recurrent infections and autoimmune diseases: A retrospective study of Chinese patients in the past 40 years. 61
32181282 2020
50
Increased risk of atopic diseases in boys with meatal stenosis: a possible pathophysiological relation. 61
31375283 2020

Variations for Drug Allergy

Expression for Drug Allergy

Search GEO for disease gene expression data for Drug Allergy.

Pathways for Drug Allergy

Pathways related to Drug Allergy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.99 IL5 IL4R CD4
2 10.72 IL5 IL4R IGHE CD40LG
3 10.65 IL5 IL4R CD40LG
4 10.34 IL5 IL4R

GO Terms for Drug Allergy

Cellular components related to Drug Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 INS IL5 IL4R IGHE HSPG2 ENPP3
2 external side of plasma membrane GO:0009897 9.55 IGHE ENPP3 CD40LG CD4 ACE
3 extracellular space GO:0005615 9.4 TPT1 INS IL5 IL4R HSPG2 GPT

Biological processes related to Drug Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.35 IL5 IL4R IGHE CD40LG CD4
2 negative regulation of blood vessel diameter GO:0097756 8.62 INS CRP

Molecular functions related to Drug Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP4A ATP12A
2 potassium-transporting ATPase activity GO:0008556 8.96 ATP4A ATP12A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP4A ATP12A

Sources for Drug Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....